finance.yahoo.com ·
tactile systems tcmd q2 2025 203118505
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedTactile Systems Technology, a medical device company, reported mixed Q2 2025 results: revenue growth driven by airway clearance, but EBITDA margin compression from increased investment in sales force and technology. The company is expanding its sales force to drive future lymphedema treatment access. Impact is single-company-specific; no broader sector or commodity price signal.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Tactile Systems Technology Q2 2025 revenue $78.9M, +7.8% YoY
- Lymphedema revenue $66M (+2% YoY), airway clearance revenue $12.9M (+51.6% YoY)
- Adjusted EBITDA $7.7M, -15% YoY due to investments in technology and sales personnel
- Sales force expanded to 293 representatives, targeting >300 by end of 2025
Tactile Systems' lymphedema and airway clearance devices face flat performance in the immediate term due to EBITDA margin compression; expected impact is flat to -2% in 48h.
Sign in to see all sector verdicts, full thesis and counter-argument debate.